Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease

Sisi Zhou,Zeyu Huang,Wenjing Hou,Yiting Lin,Jing Yu
DOI: https://doi.org/10.1007/s00011-023-01828-7
IF: 6.986
2024-01-04
Inflammation Research
Abstract:Adalimumab monotherapy can suppress gut inflammation and induce remission in active Crohn's disease but has some limitations. Exclusive enteral nutrition (EEN) is recommended for patients with mild to moderate Crohn's disease (CD), but implementation is challenging.
immunology,cell biology
What problem does this paper attempt to address?